Brian Rini, MD, FASCO
Brian I. Rini, MD, FASCO, is Ingram Professor of Medicine and Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and co-host of The Uromigos podcast.
Articles by Brian Rini, MD, FASCO
Drs. Rini and Plimack discuss the "negative" findings from CONTACT-03.
Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data.
Drs. Rini and Plimack discuss the CLEAR and KEYNOTE-426 RCC updates.
The panel provides their concluding thoughts on the frontline and refractory RCC treatment landscape.
The panel discusses treatment options in the refractory RCC setting.
The panel discusses what is most exciting to them in the frontline RCC field.
The panel discusses toxicity management and use of precision medicine.
The panelists debate the use of IO/IO versus IO/TKI regimens for frontline RCC therapy.
Dr. Rini describes the CLEAR and KEYNOTE-426 studies presented at ASCO 2023.
The panel discusses the approach to frontline treatment selection for patients with RCC.
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
In the final segment of a debate series, Brian Rini, MD, and Monty Pal, MD, debate RCC adjuvant therapeutic options.
The panel shares interesting clinical trial data in development, including CONTACT-03, TiNivo-2, and more.
The panel discusses triplet combinations in development for RCC.
The panel discusses the disappointing results of the COSMIC-313 trial.
In the second segment of a debate series, Drs. Rini and Pal address kidney cancer clinical trials of interest.
The panel discusses treatment-related toxicities and when to consider stopping treatment.
In a debate series between Brian Rini, MD, and Monty Pal, MD, they discuss frontline RCC treatment options.
The panel compares three treatment regimens.
The panel discusses the CheckMate 8Y8 clinical trial.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.